HUB Investment Partners LLC Has $293,000 Stock Position in Novartis AG (NYSE:NVS)

HUB Investment Partners LLC decreased its position in shares of Novartis AG (NYSE:NVS) by 4.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,013 shares of the company’s stock after selling 125 shares during the period. HUB Investment Partners LLC’s holdings in Novartis were worth $293,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of NVS. King Luther Capital Management Corp boosted its position in Novartis by 9.7% during the third quarter. King Luther Capital Management Corp now owns 10,442 shares of the company’s stock valued at $1,201,000 after purchasing an additional 919 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Novartis by 13.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 157,256 shares of the company’s stock valued at $18,088,000 after purchasing an additional 18,990 shares during the last quarter. Raymond James Trust N.A. lifted its position in shares of Novartis by 6.7% in the third quarter. Raymond James Trust N.A. now owns 15,384 shares of the company’s stock worth $1,769,000 after buying an additional 963 shares during the last quarter. Citigroup Inc. lifted its position in shares of Novartis by 17.0% in the third quarter. Citigroup Inc. now owns 294,178 shares of the company’s stock worth $33,836,000 after buying an additional 42,642 shares during the last quarter. Finally, CFS Investment Advisory Services LLC lifted its position in shares of Novartis by 14.4% in the third quarter. CFS Investment Advisory Services LLC now owns 2,411 shares of the company’s stock worth $277,000 after buying an additional 304 shares during the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Trading Down 1.0 %

Novartis stock opened at $112.11 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.84 and a current ratio of 1.04. The business’s 50-day simple moving average is $106.67 and its 200-day simple moving average is $107.41. The firm has a market capitalization of $229.15 billion, a PE ratio of 19.07, a PEG ratio of 1.70 and a beta of 0.53. Novartis AG has a 52 week low of $92.35 and a 52 week high of $120.92.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. Equities research analysts forecast that Novartis AG will post 8.45 earnings per share for the current year.

Novartis Dividend Announcement

The company also recently declared a dividend, which was paid on Wednesday, March 12th. Investors of record on Wednesday, March 12th were paid a dividend of $3.8695 per share. The ex-dividend date was Wednesday, March 12th. Novartis’s dividend payout ratio is 42.69%.

Analysts Set New Price Targets

NVS has been the subject of a number of analyst reports. Barclays reaffirmed an “underweight” rating on shares of Novartis in a research report on Monday, February 3rd. Morgan Stanley initiated coverage on Novartis in a research report on Wednesday, February 12th. They issued an “underweight” rating for the company. UBS Group reaffirmed a “neutral” rating on shares of Novartis in a research report on Thursday, February 13th. StockNews.com raised Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 8th. Finally, Deutsche Bank Aktiengesellschaft raised Novartis from a “hold” rating to a “buy” rating in a research report on Tuesday, February 4th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $123.38.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.